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Abstract 
This study explored the differences in treatment progress between men and women who 
were addicted to drugs. The differential rate of completion of/dropout from treatment in 
men and women with substance dependence was established. Moreover, comparisons 
between completers and dropouts, accounting for gender, were carried out for several 
variables related to treatment progress and clinical profile. A sample of 183 addicted 
patients (96 male and 87 female) who sought outpatient treatment between 2002 and 
2006 was assessed. Information on socio-demographic, consumption and associated 
characteristics was collected. A detailed tracking of each patient's progress was 
maintained for a minimum period of eight years to assess treatment progression. The 
treatment dropout rate in the whole sample was 38.8%, with statistically significant 
differences between women (47.1%) and men (31.3%). Women who dropped out of 
treatment presented a more severe profile in most of the psychopathologic variables 
than women who completed it. Moreover, women who dropped out from treatment 
presented a more severe profile than men who dropped out. According to these results, 
drug-addicted women showed worse therapeutic progress than men with similar 
histories. Thus, women must be provided with additional targeted intervention to 
promote better treatment outcomes. 
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Introduction 
In recent years, several studies have explored gender differences in drug-
addicted patients undergoing treatment (Brady, Back, and Greenfield 2009; Greenfield 
et al. 2007; Walitzer and Dearing 2006). The results of these studies have shown that 
the profiles of men and women with substance abuse or dependence are not necessarily 
the same. The development of, the motivations for and the consequences of substance 
abuse may differ between sexes (Bravo de Medina, Echeburúa, and Aizpiri 2008; 
Fernández-Montalvo et al. 2014; Hser et al. 2003; Najavits and Lester 2008; 
Wetherington 2007).  
For example, women begin using substances later than men do (Hser et al. 2003; 
Picci et al. 2012); however, they develop more severe addictions in terms of 
consequences (mainly medical, labor, economic, legal, family and social) derived from 
the consumption (Fernández-Montalvo et al. 2014; Green 2006; Grella, Scott, and Foss 
2005) and associated psychopathologic symptoms (primarily anxiety and mood 
disorders) (Bravo de Medina, Echeburúa, and Aizpiri 2008; Colpaert et al. 2013; 
Greenfield et al. 2010; Najavits and Lester 2008; Landa et al. 2006). Moreover, 
women’s addictions are also associated with a greater impact on their families, social 
life and employment (Storbjörk 2011; Walitzer and Dearing 2006). Furthermore, recent 
studies have shown a greater likelihood of the presence of a history of lifetime 
maltreatment and sexual abuse among female than male addicts attending treatment 
(Fernández-Montalvo, López-Goñi, and Arteaga 2015; Sacks, McKendrick, and Banks 
2008). This further complicates the clinical picture that addicted women present, with 
more associated psychopathologic comorbidity when they seek treatment than men 
(Fernández-Montalvo et al. 2015). In comparison, male addicts tend to have more legal 
problems arising from substance consumption and a higher rate of antisocial personality 
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disorder than female addicts (Hser et al. 2003; Miquel et al. 2011; Najavits and Lester 
2008). 
 Multiple studies have examined potential gender differences in severity and 
course of addiction, as well as in motivation for treatment, treatment efficacy, and 
therapeutic outcomes, but the results have been inconsistent. While some studies have 
observed that women have a greater motivation for treatment, greater involvement in 
self-help activities and a better therapeutic outcome (Grella, Scott, and Foss 2005; 
López-Goñi et al. 2008; Najavits and Lester 2008), other studies have reported that 
gender is not directly related to treatment adherence and/or completion (Greenfield et al. 
2007; Hser et al. 2003; Fernández-Montalvo et al. 2007, 2008). Furthermore, some 
inconsistency has been observed across studies regarding the specific relationship 
between gender and dropping out from treatment. While several studies have found that 
a significantly greater proportion of female addicts dropout, other studies have shown 
that male gender is a better predictor of dropping out of treatment (Brorson, et al. 2013). 
These contradictory results could be related to the different types of samples 
used for studying dropouts (e.g., ambulatory versus residential setting), together with 
the different risk factors for dropout found for men and women. For example, in the 
Drug Abuse Treatment Outcome Study (DATOS), men were more likely to drop out of 
outpatient drug-free programs, whereas women were more likely to be categorized in 
the low-retention group for outpatient methadone treatment (Simpson et al. 1997). 
Gender differences in the prediction of treatment retention or dropout have been found 
(Brorson, et al. 2013). However, despite evidence that men and women have different 
experiences of treatment initiation and completion, the factors that predict these 
outcomes have not been reliably established. Additional studies are needed to 
characterize addiction treatment better in females compared to males. Elucidation of 
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these differences may contribute to the future development of more effective, gender-
specific treatment strategies. 
Therefore, the general goal of this study was to analyze the differential treatment 
progress of men and women addicted to drugs (mainly alcohol and cocaine). 
Specifically, the main objectives of this study were: 1) to establish the differential rate 
of completion and dropout of treatment in men and women with substance dependence; 
2) compare completers and dropouts accounting for gender, in the number of treatment 
episodes, the time invested in treatment and psychopathological symptoms and 3) 
compare men and women, taking into account treatment completion, in the same 
variables mentioned above.  
Method 
The protocol for this study was approved by the ethics committees of the Public 
University of Navarre and of the “Fundación Proyecto Hombre de Navarra”. Informed 
consent was written and signed by all participants. 
Participants 
The initial sample consisted of 195 consecutive addicted patients (100 male and 
95 female) who sought treatment for their addictions for the first time and entered 
treatment at the “Fundación Proyecto Hombre de Navarra” (Spain) between 2002 and 
2006. This was 100% of patients who sought treatment for the first time during this 
period. Treatment was a cognitive-behavioral intervention with two different modalities 
(outpatient and inpatient treatment) aimed at abstinence. The main therapeutic 
techniques were related to stimulus control and in vivo exposure, as well as to relapse 
prevention. Successful program completion typically requires approximately 12 months 
and was achieved when a patient completed all of the therapeutic sessions. Both 
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outpatient and inpatient modalities have been effective in the treatment of addictions 
(Fernández-Montalvo and López-Goñi 2010; Fernández-Montalvo et al. 2008). 
The inclusion criteria for this study were that the patients had to: a) meet the 
diagnostic criteria of substance dependence according to the DSM-IV-TR (American 
Psychiatric Association 2000); b) be between 18 and 65 years of age; c) be receiving 
treatment for their addiction for the first time; d) sign informed consent to participate in the 
study; and e) complete two baseline assessment sessions. Following these criteria, 12 
people (6.2% of the initial sample) were excluded from the study. Therefore, the final 
sample was 183 participants (96 male and 87 female), 93.8% of the initial sample. 
Assessment 
The European Addiction Severity Index (EuropASI; Kokkevi and Hartgers 
1995) is the European version of the Addiction Severity Index (ASI; McLellan et al., 
1980). This tool yields Interviewer Severity Ratings (ISR).  The ISR assess the need for 
treatment in the following seven areas: a) general medical state (16 items), b) labor and 
economic situation (26 items), c) drug consumption (28 items), d) alcohol consumption 
(16 items), e) legal problems (23 items), f) family and social relationships (26 items), 
and g) psychiatric state (22 items). Severity scores range from 0 (no problem) to 9 
(extreme problem) in each area, and the cut-off point indicating an additional need for 
treatment in each area is 4. These areas are directly related to the severity of 
consumption in terms of the consequences derived from the addiction (López-Goñi et 
al. 2010). The Spanish version of the EuropASI was developed by Bobes et al. (1996).  
The ISR have been used in several studies because they offer relevant information about 
addiction severity (López-Goñi, Fernández-Montalvo, and Arteaga 2012). The three-
day test–retest reliabilities of the ASI severity ratings have been reported to be greater 
than or equal to 0.92 for all domains (McLellan et al. 1985). The one-week test-retest 
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reliabilities of the Spanish version used in this study ranged from 0.67 to 0.96 in the 
seven different areas (González et al. 2002). The alpha coefficients for the current 
sample were 0.70 for the ISR scores. Regarding specific scales, alpha coefficients were 
0.81 (general medical scale), 0.78 (labor and economic situation), 0.80 (drug 
consumption), 0.86 (alcohol consumption), 0.88 (legal problems), 0.73 (family and 
social relationships), and 0.82 (psychiatric state). 
Moreover, in this study, some items of the EuropASI were used to obtain 
specific information about the age at first consumption (defined as a complete 
consumption of a substance, e.g. a regular drink), the number of years of regular 
consumption (defined as a consumption with a frequency of three or more times per 
week or two-day binges) and the substance that motivated treatment (based on the 
interviewer’s criteria after assessing the years of use, number of treatments and number 
of overdoses). The specific items of the EuropASI to assess these variables were the 
items 1, 2, 7, 9, and 18 of the Drug and Alcohol use scale. Furthermore, the presence of 
psychopathologic problems in the sample was obtained from the Psychiatric scale 
(items 3-10). These items are the following: Medication for psychiatric or emotional 
problems, severe depression, anxiety problems, cognitive problems, hallucinations, 
suicide ideation, problems of violence control, and suicide attempts (lifetime and past 
30 days). The Cronbach’s alpha for these items was 0.76. 
Procedure 
Once the clinical sample was selected using the criteria described above, the 
baseline assessment of the sample was carried out in two sessions before beginning the 
treatment. All participants were interviewed by clinical psychologists who had eight or 
more years of experience in treating addictions and in applying the EuropASI. Sessions 
occurred once per week for two weeks; the time interval between sessions was the same 
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for each participant (one week). In the first session, data related to socio-demographic 
characteristics (mainly age, gender, marital status, and employment situation) and drug 
consumption (mainly age at first consumption, years of consumption, substance that 
motivated treatment, addiction severity) were collected using the EuropASI. In the 
second session, the presence of psychological symptoms and problems, as well as data 
related to previous treatment, was assessed. After the assessment sessions, patients 
began the standard treatment of “Proyecto Hombre” for addiction.  
To establish the EuropASI scores, the procedure used was the two-step 
methodology suggested by Bobes et al. (2008). First, the ratings of the seven areas of 
assessment were calculated based on the interviewer's judgement derived from the 
patient’s answers, and yielded a score ranging from 0 (no problem) to 9 (extreme 
problems) in each area. Second, after concluding the interview, the intervention team, 
blind to the participant’s identity, validated the interviewer’s scores reviewing the 
answers of each patient. If a discrepancy was observed, the intervention team 
reappraised the patient’s answers to reach an agreement. 
Detailed tracking of each patient's progress was maintained to assess whether the 
patient completed the treatment by obtaining a therapeutic discharge or whether the 
patient dropped out of the treatment before the conclusion of the program (i.e., 
abandoned the treatment before obtaining a therapeutic discharge). Moreover, all of the 
patients in the sample were tracked since the beginning of the treatment for a minimum 
of eight years for the purpose of assessing the number of subsequent re-entries into the 
addiction treatment program.  
Data Analyses 
Descriptive analyses were conducted for all variables. Bivariate analyses were 
employed using χ2 or t-test statistics, depending on the nature of the variables studied, 
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as well as Pearson’s correlations. Statistical tests (alpha = 0.05 considered statistically 
significant) for all of the analyses were provided. Standardized effect size (Cohen’s d) 
and statistical significance for all of the analyses were provided. Moreover, four 
discriminant analyses were carried out to determine which of the variables related to 
number and duration of treatment episodes were associated with gender and treatment 
completion. Additionally, six multiple logistic regression analyses (using the forward 
method) were conducted to determine the psychopathologic variables related to gender 
(3 models) and to treatment completion (3 models). All psychopathologic symptoms 
from the EuropASI (lifetime and past 30 days) were included in the models. The 
variable entry criterion was set to 0.05 and the variable retention criterion to 0.10. The 
Hosmer–Lemeshow test was used to assess the goodness of fit of these models. A 
difference of p < 0.05 was considered significant. Statistical analyses were carried out 
using SPSS (version 15.0 for Windows) and G*Power 3 (Faul et al. 2007). 
Results 
Socio-demographic and Consumption Characteristics at Baseline 
The mean age of the individuals included in the study was 36.4 years (SD = 9.9 
years), and mean age did not differ significantly between men and women; the sample 
included 96 (52.4%) men and 87 (47.6%) women (Table 1). A majority of the 
participants were unmarried (n =102; 55.7%), without significant differences in marital 
status between men and women. The rate of unemployment was significantly higher in 
women (19.5%) than in men (2.1%). The main substances that motivated treatment 
were alcohol (n = 84; 45.9%) and cocaine (n = 72; 39.3%), followed by other 
substances (e.g., heroin, cannabis, amphetamine, etc.) in smaller numbers (n = 27; 
14.7%), with no significant differences in this variable between men and women. 
INSERT TABLE 1 
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Unadjusted comparison of consumption characteristics showed a longer time of 
alcohol consumption in men than in women (Table 1). However, no significant 
differences were observed between men and women in the duration of consumption of 
cocaine and cannabis. 
Regarding addiction severity, the highest scores in the EuropASI were obtained 
for the family/social, alcohol use, drug use and psychiatric scales with statistically 
significant differences between men and women. Drug-addicted men scored higher than 
women on the legal scale, while women showed higher scores on the scales related to 
medical, employment/support, family/social and psychiatric problems. 
Rate of Completion and Dropout from Treatment 
The rate of treatment dropout in the whole sample was 38.8% (n = 71), with 
statistically significant differences by gender (p = 0.028) with more women who 
dropped out of the treatment (n = 41; 47.1%) than men (n = 30; 31.3%).  
Number of Treatment Episodes and Months in Treatment during the 8+ Year 
Follow-up 
The total sample had 343 treatment episodes (number of times that they had 
sought treatment for their addiction, independently of the therapeutic result), with a 
mean of 1.9 episodes per patient. Of these episodes, 72.3% (n = 248) were conducted in 
an outpatient basis, and 27.7% (n = 95) were conducted in a therapeutic community. 
The 96 men had a total of 181 treatment episodes, and the 87 women had 162 episodes. 
Comparisons between men and women in the average number of treatment episodes did 
not differ significantly.  
Significant positive correlations were found between the number of treatment 
episodes and severity of the addiction (assessed by the EuropASI the first time patients 
sought treatment at baseline) (Table 2).  
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INSERT TABLE 2 
 The participants spent a mean of 22.8 months (SD = 16.2 months) in treatment 
(total months after summing the different episodes of treatment), without statistically 
significant differences between men (mean = 22.8; SD = 14.6) and women (mean = 
22.9; SD = 17.8); t = 0.1 (p = 0.18). Moreover, significant positive correlations between 
months in treatment and severity of the addiction were found (Table 2).  
Comparisons by Gender and Treatment Completion 
 INSERT TABLE 3 
The men who dropped out of treatment had a greater number of treatment 
episodes than the men who completed treatment (Table 3). Among women, no 
statistically significant differences were observed in number of treatment episodes 
between completers and dropouts. Further, significant differences were not found in 
comparisons between the men and women who dropped out of treatment or between the 
men and women who completed treatment.  
Four discriminant analyses were then carried out to determine variables related 
to gender and treatment completion. The results of the step-wised discriminant analyses 
with the five variables studied showed that only one discriminant analysis was 
significant (Wilks Lambda = 0.94, p = 0.018): the variables related to treatment 
completion in men. Specifically, the number of treatment episodes (on an inpatient 
basis) adequately classified 69.8% of cases.   
Comparison in Psychopathological Variables 
  Women who dropped out of treatment presented a more severe 
psychopathologic symptom profile in most of the variables studied than women who 
completed treatment (Table 4). However, men showed no significant differences in such 
symptom severity between completers and dropouts. 
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When psychopathologic symptoms were compared between men and women, 
while accounting for treatment completion, women who dropped out of treatment 
presented a more severe profile than the men who dropped out. In the case of 
completers, women presented more lifetime depression than men, but fewer violence 
problems in the last 30 days. 
INSERT TABLE 4 
 Next, six multiple logistic regression analyses were performed to determine 
which specific psychopathologic variables were most relevant in differentiating between 
men and women, as well as between treatment completion and dropout (Table 5). The 
variables for which the regression analyses were adjusted were (both lifetime and past 
30 days): medication for psychiatric or emotional problems, severe depression, anxiety 
problems, cognitive problems, hallucinations, suicide ideation, violence control 
problems and suicide attempts. 
INSERT TABLE 5 
 The therapeutic discharge in the whole sample was related to not having anxiety 
problems in the last 30 days and not having suicide ideation. In the case of men, no 
variables were significantly associated with treatment completion, and no significant 
differences were observed in any variable between men who dropped out the treatment 
program and those who completed it. However, women without anxiety problems in the 
last 30 days and without long-life suicide ideation had higher probabilities of treatment 
completion.  
 Patients without anxiety problems or long-life suicide ideation had more 
probabilities of being men. Further, completers without anxiety problems and without 
problems of violence control in the last 30 days were mainly men. Finally, dropouts 
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without anxiety problems and without suicide ideation had higher probabilities of being 
men. 
Discussion 
 This study analyzed the differential treatment progress for women and men with 
substance dependence. Previous studies have shown differential profiles by gender 
when patients with substance dependence sought treatment for the first time 
(Fernández-Montalvo et al. 2014; Storbjörk 2011; Walitzer and Dearing 2006). 
Members of each gender in our study’s sample, as in other studies, presented a different 
profile when they were assessed at the entry of the treatment. Specifically, women had a 
more severe addiction severity profile. Despite these differences, little is known about 
how different the progress of women and men is during the treatment for their drug 
addiction. This paper aimed to begin to approach this, and the results of this paper 
support the existence of gender differences in treatment progress of patients with a 
problem of addiction. 
 Women in this study dropped out of treatment at a higher rate than men, which 
is an important finding because treatment dropout has been shown to be an important 
predictor of relapse and worse therapeutic progress (Brorson et al. 2013; Grella et al. 
1999; Fernández-Montalvo et al. 2007). This correlation is most likely related to the 
different situations found in women than in men when they seek treatment. For 
example, in recent studies of our research group (Fernández-Montalvo et al. 2014; 
Fernández-Montalvo et al. 2008), women seemed to be more reluctant to seek 
treatment, and when they decided to seek out consultation about their addiction 
problems, they were in a more severe situation and with a higher impact in the main 
areas of life. These results highlight the need for the development of specific strategies 
to make treatment more accessible to women and to include more accurate therapeutic 
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techniques to avoid women’s disproportionately higher dropout rate. Therefore, 
therapists should attend to the specific comorbidities (anxiety, depression, suicidal 
ideation, etc.) and risk factors (medical problems, unemployment, and poor social and 
family support) found in women, when they tailor the clinical interventions. 
 We also assessed a frequent event in treatment programs for drug-addicted 
patients: the number of treatment episodes. A total of 343 episodes were observed, with 
a mean of 1.9 episodes of treatment by patient. No statistically significant differences 
were observed in number of treatment episodes between men and women. This high rate 
of treatment re-entries (number of times leaving and re-entering the treatment program) 
coincides with those from previous studies (Dennis et al. 2005; López-Goñi et al. 2014). 
In recent decades, the interest in this subtype of patients who, despite receiving 
treatment, alternate between periods of abstinence (or more controlled drug use) and 
periods of relapse and re-admission into treatment programs has increased (Dennis and 
Scott 2007; Hser, Longshore, and Douglas 2007). Studies conducted in this field show 
that re-admitted patients generally have a more severe profile than those who respond to 
first time treatment. In general, patients who re-enter treatment programs are older and 
with lower educational attainment than first-time admits; re-admitted patients also have 
lower job stability, more problems with the law, and more medical, psychiatric, and 
family problems than patients who seek treatment for the first time (Cacciola, Leggett, 
and Camilleri 2009; Hser et al. 1999; López-Goñi et al. 2014; Moos, Moos, and Finney 
2001). The results of the present study support these findings, as the number of 
treatment episodes was positively correlated with the severity of the addiction in all 
areas assessed by the EuropASI, although with differences between men and women. 
While the number of treatment episodes for men was related to a greater severity in 
family/social, alcohol use, employment/support and psychiatric areas, the number of 
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treatment episodes for women was related to legal, drug use, psychiatric and medical 
problems. These results highlight the importance of an accurate assessment and 
treatment the first time addicted patients go to treatment. 
Results derived from comparisons between men and women (taking into account 
treatment completion) and between completers and dropouts (taking into account 
gender) showed important clinical repercussions for the development of different 
therapeutic strategies in treatment of men and women with substance dependence. For 
instance, men who dropped out of treatment appeared to have a higher probability of 
dropping out during future clinical interventions; in fact, men who dropped out of 
treatment actually had more treatment episodes. However, these results were not found 
in women. Women who dropped out of treatment showed more associated 
psychopathological symptoms than women who completed it, which was not observed 
as a difference for men. Moreover, women who dropped out of treatment had a worse 
psychopathological profile than men who dropped out; in fact, the most severe 
psychopathological profile was found in women who dropped out of treatment. These 
results coincide with those found in previous studies about gender and/or treatment re-
entry in drug-addicted patients (Cacciola, Leggett, and Camilleri 2009; Fernández-
Montalvo et al. 2014; Grella, Scott, and Foss 2005; Hser, Longshore, and Douglas 
2007; López-Goñi et al. 2014; Storbjörk 2011). 
This study has several limitations that should be considered. The first limitation 
was related to the evaluated sample. Our study included patients who sought treatment 
at a specialized center. Undoubtedly, this creates a bias that prevents us from 
generalizing the results to all addicted patients. Second, this was a correlational study 
that did not account for other potential factors related to the differences. Future studies 
should consider other factors that may explain why men and women differ in 
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therapeutic progress. Moreover, the present study only included patients who had 
finished the assessment; patients who did not complete the two assessment sessions 
were not considered. We assume that patients who withdrew from treatment at an early 
stage had different profiles from those of patients analyzed in this study. On the other 
hand, this is an exploratory study with stepwise regression analyses. Future studies 
should confirm the relevance of the obtained variables with confirmatory methods. 
Finally, this study did not analyze the influence of the type of treatment received 
(inpatient or outpatient) on the differential therapeutic progression of men and women. 
In this study patients could have received both types of treatment as a part of their own 
therapeutic progression. Consequently, both types of treatment were not exclusive. 
Future studies should take into account the influence of the specific type of treatment on 
therapeutic progression. Due to these limitations, we must be cautious when attempting 
to generalize our results. 
In any case, the data found in this study support the notion that addicted women 
in treatment have a profile that distinguishes them from addicted men. Moreover, 
treatment progress seems to differ by gender. Therefore, it is necessary to continue to 
study addiction with a focus on gender. These studies will allow a better understanding 
of the factors that increase resistance to treatment and an adaptation of existing 
intervention programs to meet the specific needs of men and women with substance 
abuse problems.  
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Table 1. Socio-demographic and consumption characteristics of the sample at baseline by 
gender 
 
 Total (N= 183) 
Females 
(n = 87) 
Males 
(n = 96) t (df) p 
(1 – β 
err. 
Prob.)  Mean (±SD) Mean (±SD) Mean (±SD) 
Mean age, years  36.4 (9.9) 35.1 (9.1) 37.6 10.5 1.7 (175) .102 .73 
Age, years, at first consumption            
Alcohol 17.6 (4.8) 17.9 (4.8) 17.5 (4.7) 0.5 (162) 0.583 0.14 
Alcohol to intoxication 24.2 (7.9) 27 (8.0) 21.8 (7.1) 4.2 (141) p < 0.001 0.99 
Cocaine 23.0 (6.1) 22.3 (5.4) 23.4 (6.4) 0.9 (117) 0.351 0.24 
Cannabis 16.9 (3.8) 17.5 (4.9) 16.3 (2.5) 1.3 (54.5) 0.192 0.41 
Years of consumption           
Alcohol 14.7 (10.6) 12.7 (9.5) 16.3 (11.0) 2.2 (157) 0.031 0.69 
Alcohol to intoxication 10.7 (9.6) 8.5 (7.4) 12.3 (10.5) 2.5 (136.0) 0.015 0.75 
Cocaine 5.6 (5.3) 6.5 (6.0) 5.4 (4.8) 1.1 (108) 0.280 0.28 
Cannabis 10.1 (7.4) 9.7 (7.7) 10.6 (7.1) 0.6 (81) 0.575 0.14 
Addiction severity (ISR)           
Medical 2.1 (1.6) 2.4 (1.8) 1.8 (1.3) 2.8 (153.6) 0.006 0.78 
Employment/Support 2.6 (1.9) 3.1 (2.0) 2.1 (1.6) 3.7 (163.2) p < 0.001 0.98 
Legal 1.5 (1.4) 1.2 (1.3) 1.7 (1.5) 2.4 (174.7) 0.016 0.73 
Family/Social 4.0 (1.8) 4.6 (1.7) 3.6 (1.7) 3.8 (177) p < 0.001 0.98 
Psychiatric 3.5 (1.9) 4.1 (1.7) 2.9 (1.8) 4.6 (177) p < 0.001 0.99 
Alcohol use 3.8 (2.2) 3.6 (2.2) 3.9 (2.1) 1.0 (177) 0.309 0.26 
Drugs use 3.5 (2.2) 3.5 (2.3) 3.4 (2.1) 0.3 (176) 0.772 0.17 
 N (%) n (%) n (%) X2 (df) 
 (1 – β 
err. 
Prob.) 
Marital status           
Single 102 (55.7%) 46 (53.0%) 56 (58.3%) 
1.5 
   
Married 49 (26.8%) 27 (31.0%) 22 (22.9%) (2) 0.460 0.13 
Divorced 32 (17.5%) 14 (16.0) 18 (18.7%)    
Employment situation           
Employed 155 (84.7%) 63 (72.4%) 92 (95.8%) 
19.6 
   
Unemployed 19 (10.4%) 17 (19.5%) 2 (2.1%) (2) p < 0.001 0.99 
Other (student, retired, etc.) 9 (4.9%) 7 (8.0%) 2 (2.1%)    
Substance that motivated 
treatment        
   
Alcohol 84 (45.9%) 42 (48.3%) 42 (43.7%)     
Cocaine 72 (39.3%) 28 (31.2%) 44 (45.8%) 4.9 (2) 0.085 0.38 
Others (heroin, cannabis, etc.) 27 (14.7%) 17 (19.5%) 10 (10.4%)     
ISR = Interviewer Severity Rating 
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Table 2. Correlations between the number of treatment episodes during the 8+ year 
follow-up and severity of the addiction at baseline by gender 
 Number of treatment episodes Total months in treatment 
EuropASI (ISR) Total (p) 
Female 
(p) 
Male 
(p) 
Total 
(p) 
Female 
(p) 
Male 
(p) 
Medical 0.197 (0.008) 
0.284 
(0.006) 
0.066 
(0.517) 
0.213 
(0.004) 
0.254 
(0.014) 
0.137 
(0.175) 
Employment/Support 0.229 (0.002) 
0.12 
(0.251) 
0.335 
(0.001) 
0.101 
(0.178) 
0.026 
(0.803) 
0.213 
(0.034) 
Legal 0.190 (0.011) 
0.337 
(0.001) 
0.076 
(0.459) 
0.085 
(0.262) 
0.047 
(0.657) 
0.097 
(0.341) 
Family/Social 0.429 (p<0.001) 
0.253 
(0.016) 
0.545 
(p<0.001) 
0.302 
(p<0.001) 
0.143 
(0.176) 
0.452 
(p<0.001) 
Psychiatric 0.305 (p<0.001) 
0.305 
(0.003) 
0.303 
(0.002) 
0.175 
(0.019) 
0.085 
(0.420) 
0.253 
(0.012) 
Alcohol use 0.301 (p<0.001) 
0.257 
(0.014) 
0.383 
(p<0.001) 
0.336 
(p<0.001) 
0.353 
(0.001) 
0.331 
(0.001) 
Drugs use 0.225 (0.003) 
0.337 
(0.001) 
0.137 
(0.175) 
-0.037 
0.624 
-0.1 
(0.219) 
0.058 
(0.567) 
ISR = Interviewer Severity Rating 
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Table 3. Comparisons in treatment episodes and months in treatment by gender 
 
 GENDER 
 
Female 
(n = 87) 
Male 
(n = 96) 
 
Dropouts 
(n = 41) 
Completers 
(n = 46) t (df) p (1 – β err. Prob.) 
Dropouts 
(n = 30) 
Completers 
(n = 66) t (df) p (1 – β err. Prob.) 
 Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD) 
TE (outpatient) 1.4 (0.9) 1.1 (0.6) 1.5 (64.9) 0.133 0.44 1.8 (1.1) 1.3 (0.8) 2.1 (43.6) 0.039 0.75 
TE (inpatient) 0.7 (1.0) 0.5 (1.1) 0.6 (85) 0.539 0.25 0.6 (1.2) 0.3 (0.6) 1.2 (37.0) 0.225 0.44 
TE (total) 2.1 (1.3) 1.7 (1.5) 1.3 (85)  0.186 0.37 2.4 (1.8) 1.6 (1.2) 2.1 (40.1) 0.046 0.75 
MT (maximum) 14.5 (11.8) 19.5 (12.3) 1.9 (85) 0.055 0.60 18.7 (11.9) 16.6 (8.5) 0.8 (42.9) 0.400 0.25 
MT (total) 20.1 (15.3) 25.4 (19.7) 1.4 (85)  0.161 0.40 26.1 (17.1) 21.1 (13.5) 1.4 (46.1) 0.171 0.45 
 TREATMENT COMPLETION 
 Dropouts (n = 71) 
Completers 
(n = 112) 
 Female (n = 41) 
Male 
(n = 30) t (df) p (1 – β err. Prob.) 
Female 
(n = 46) 
Male 
(n = 66) t (df) p (1 – β err. Prob.) 
 Mean (±SD) Mean (±SD) Mean (±SD) Mean (±SD) 
TE (outpatient) 1.4 (0.9) 1.8 (1.1) 1.6 (69) 0.122 0.45 1.1 0.6 1.3 0.8 1.3 (110) 0.207 0.35 
TE (inpatient) 0.7 (1.0) 0.6 (1.2) 0.2 (69) 0.848 0.07 0.5 1.1 0.3 0.6 1.1 (66.1) 0.287 0.31 
TE (total) 2.1 (1.3) 2.4 (1.8) 0.9 (69) 0.381 0.22 1.7 1.5 1.7 1.2 0.1 (110) 0.929 0.06 
MT (maximum) 14.5 (11.9) 18.7 (11.9) 1.5 (69) 0.145 0.42 19.5 12.3 16.6 8.5 1.4 (74.0) 0.170 0.43 
MT (total) 20.1 (15.3) 26.1 (17.1) 1.6 (69) 0.124 0.66 25.4 19.7 21.1 13.5 1.4 (110) 0.173 0.39 
TE = Treatment episodes; MT (maximum) = Months in treatment during the longest episode; MT (total) = Total sum of months in treatment 
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Table 4. Comparisons in psychopathologic variables (lifetime and past 30 days) by gender 
 GENDER 
 Female (n = 87) 
Male 
(n = 96) 
Psychopathologic 
symptoms 
Dropouts 
(n = 41) 
Completers 
(n = 46) X2 
(df = 1) p 
1 – β err. 
Prob  
Dropouts 
(n = 30) 
Completers 
(n = 66) X2 
(df = 1) p 
1 – β err. 
Prob (Lifetime) n (%) n (%) n (%) n (%) 
Medication for psychiatric or 
emotional problems 28 (68.3%) 21 (45.6%) 4.5 0.034 0.21 12 (40%) 30 (45.4%) 0.2 0.618 0.06 
Severe depression 35 (85.4%) 29 (63.0%) 5.5 0.018 0.47 16 (53.3%) 28 (42.4%) 1.0 0.320 0.10 
Anxiety problems 37 (92.5%) 36 (78.3%) 3.4 0.066 0.32 19 (63.3%) 34 (51.5%) 1.2 0.280 0.11 
Cognitive problems 20 (48.8%) 24 (52.2%) 0.0 0.841 0.05 8 (26.7%) 24 (36.4%) 0.9 0.350 0.10 
Hallucinations 7 (17.1%) 5 (10.9%) 0.6 0.425 0.07 2 (6.7%) 15 (22.7%) 3.6 0.056 0.48 
Suicide ideation  32 (78.1%) 21 (45.6%) 9.6 0.002 0.74 13 (43.3%) 19 (28.8%) 2.0 0.161 0.15 
Problems of violence control 17 (43.9%) 18 (39.1%) 0 0.825 0.05 11 (36.7%) 26 (39.4%) 0.1 0.799 0.05 
Suicide attempts 20 (48.8%) 11 (23.9%) 5.8 0.016 0.45 4 (13.3%) 8 (12.1%) 0.0 0.910 0.05 
(Past 30 Days)           
Medication for psychiatric or 
emotional problems 24 (58.5%) 21 (45.6%) 1.4 0.230 0.12 7 (23.3%) 22 (33.3%) 1.0 0.323 0.07 
Severe depression 11 (26.8%) 12 (26.1%) 0 0.938 0.05 4 (13.3%) 12 (18.2%) 0.4 0.555 0.07 
Anxiety problems 24 (58.5%) 17 (36.9%) 4.6 0.033 0.34 9 (30.0%) 18 (27.3%) 0.1 0.783 0.05 
Cognitive problems 18 (43.9%) 15 (32.6%) 1.2 0.239 0.12 6 (20.0%) 21 (31.8%) 1.4 0.233 0.12 
Hallucinations 1 (2.4%) 2 (4.3%) 0.3 0.613 0.05 0 0 -- -- -- 
Suicide ideation  11 (26.8%) 2 (4.3%) 8.6 0.003 0.88 4 (13.3%) 2 (3.0%) 3.8 0.053 0.27 
Problems of violence control 6 (14.6%) 0 -- -- -- 1 (3.3%) 6 (9.1%) 1.0 0.315 0.15 
Suicide attempts 2 (4.9%) 1 (2.2%) 0.5 0.503 0.08 1 (3.3%) 1 (1.5%) 0.3 0.613 0.06 
 TREATMENT COMPLETION 
 Dropouts (n = 71) 
Completers 
(n = 112) 
(Lifetime) Female (n = 41) 
Male 
(n = 30) 
X2 
(df = 1) p 
1 – β err. 
Prob 
Female 
(n = 46) 
Male 
(n = 66) 
X2 
(df = 1) p 
1 – β err. 
Prob 
Medication for psychiatric or 
emotional problems 28 (68.3%) 12 (40.0%) 5.6 0.018 0.44 21 (45.6%) 30 (45.4%) 0 0.984 0.05 
Severe depression 35 (85.4%) 16 (53.3%) 8.8 0.003 0.67 29 (63.0%) 28 (42.4%) 4.6 0.032 0.36 
Anxiety problems 37 (92.5%) 19 (63.3%) 9.1 0.003 0.79 36 (78.3%) 34 (51.5%) 8.3 0.004 0.68 
Cognitive problems 20 (48.8%) 8 (26.7%) 3,9 0.049 0.31 24 (52.2%) 24 (36.4%) 2.8 0.096 0.22 
Hallucinations 7 (17.1%) 2 (6.7%) 1,7 0.193 0.18 5 (10.9%) 15 (22.7%) 2.4 0.118 0.22 
Suicide ideation  32 (78.1%) 13 (43.3%) 9.0 0.003 0.68 21 (45.6%) 19 (28.8%) 3.4 0.067 0.25 
Problems of violence control 17 (43.9%) 11 (36.7%) 0.2 0.683 0.06 18 (39.1%) 26 (39.4%) 0 0.978 0.05 
Suicide attempts 20 (48.8%) 4 (13.3%) 9.7 0.002 0.85 11 (23.9%) 8 (12.1%) 2.4 0.118 0.13 
(Past 30 Days)           
Medication for psychiatric or 
emotional problems 24 (58.5%) 7 (23.3%) 8.8 0.003 0.71 21 (45.6%) 22 (33.3%) 1.7 0.187 0.14 
Severe depression 11 (26.8%) 4 (13.3%) 1.9 0.169 0.17 12 (26.1%) 12 (18.2%) 1.0 0.316 0.09 
Anxiety problems 24 (68.5%) 9 (30.0%) 6.2 0.013 0.48 17 (36.9%) 18 (27.3%) 1.2 0.277 0.10 
Cognitive problems 18 (43.9%) 6 (20.0%) 4.8 0.029 0.41 15 (32.6%) 21 (31.8%) 0 0.930 0.05 
Hallucinations 1 (2.4%) 0 -- -- -- 2 (4.3%) 0 -- -- -- 
Suicide ideation  11 (26.8%) 4 (13.3%) 1.9 0.169 0.17 2 (4.3%) 2 (3.0%) 0.1 0.712 0.05 
Problems of violence control 6 (14.6%) 1 (3.3%) 2.5 0.115 0.35 0 6 (9.1%) -- -- -- 
Suicide attempts 2 (4.9%) 1 (3.3%) 0.1 0.749 0.06 1 (2.2%) 1 (1.5%) 0.0 0.837 0.99 
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Table 5. Results of multivariate analysis 
 
Logistic Regression: Psychopathological Variables 
(Dependent variable = Treatment completion; 0 = Dropout; 1 = Therapeutic Discharge) (Dependent variable = Gender; 0 = Male; 1 = Female) 
 Variables* OR (p) 95% CI  Variables* OR (p) 95% CI 
All Anxiety last 30 days (No) 2.08 (0.038) (1,04, 4.17) All Anxiety problems (No) 0.27 (p < 0.001) (0.14, 0.55) 
 Suicide ideation last 30 days (No) 3.74 (0.033) (1.11, 12.61)  Suicide ideation (No) 0.52 (0.035) (0.28, 0.96) 
 Suicide ideation (No) 2.73 (0.003) (1.40, 5.32)  Constant 1.94 (0.005)  
 Constant 0.17 (0.003)      
Adj. R2 0.192   Adj. R2 0.155   
        
C. classified 71.8% (Total) 91.3 % (Completers) 42.9 % (Dropouts) C. classified 63.7% (Total) 45.0% (Male) 83.9% (Female) 
Male --   Completers Anxiety problems (No) 0.25 (0.002) (0.11, 0.60) 
 Constant 2.0 (0.002)   Problems of violence control last 30 days (No) 2E+009 (0.999) (0, --) 
     Constant 0 (0.999)  
Adj. R2 0   Adj. R2 0.194   
        
C. classified 66.7% (Total) 100% (Completers) 0% (Dropouts) C. classified 65.8% (Total) 57.6% (Male) 77.8% (Female) 
Female Anxiety last 30 days (No) 2.92 (0.027) (1.13, 7.54) Dropouts Anxiety problems (No) 0.206 (0.034) (0.05, 0.89) 
 Suicide ideation (No) 4.55 (0.003) (1.70, 12.20)  Suicide ideation (No) 0.311 (0.037) (0.10, 0.93) 
 Constant 0.35 (0.009)   Constant 2.820 (0.003)  
Adj. R2 0.227   Adj. R2 0.238   
        
C. classified 70.2% (Total) 88.6% (Completers) 50.0% (Dropouts) C. classified 71.4% (Total) 66.7% (Male) 75.0% (Female) 
Adj. = Adjusted; C. classified = correctly classified 
*All psychopathological symptoms from the EuropASI (lifetime and past 30 days) were included in the models 
 
  
 
 
